Dr. Reddy’s Laboratories Ltd. has named Akhil Ravi as CEO of its wholly-owned subsidiary Aurigene Pharmaceutical Services Ltd. (APSL) effective February 1, 2022.
 
Since joining Dr. Reddy’s in 2018 from McKinsey & Company, Ravi has served as head of strategy for Services and Active Pharmaceutical Ingredients (APIs), and headed the Sales of APIs in Europe. In addition, he has also had a brief stint as Plant Head. Ravi holds a BTech degree in Chemical Engineering from IIT Bombay and an MBA from the Indian School of Business (ISB).
 
“Akhil is very well prepared for this role. He was instrumental in growing our API business through product development and an improved service experience for our B2B customers through digital platforms. His strong background in customer service, sales, strategy, and management make him an ideal leader for Aurigene, and we look forward to his accomplishments in this new role,” said Deepak Sapra, CEO of API and Services at Dr. Reddy’s and member of the Board at Aurigene.
 
Akhil Ravi said: “Aurigene Pharmaceutical Services is a dynamic partner for global pharma companies. With its integrated services from clinical research up to commercial manufacturing for small and large molecules, it is able to significantly speed up the journey of an NCE/NBE (New Chemical and Biological Entities) to the patient. I am very thrilled to join Aurigene and work with the team to serve innovative global pharma and biotech companies.”